Answers are grounded in this paper and cite their sources.
Cohort study demonstrates sex-specific bone and body composition gains during long-term growth hormone replacement in deficient adults, indicating more favorable therapeutic responses in men.
Purpose: The effects of growth hormone (GH) replacement on bone mass and body composition in adult with GH deficiency (AGHD) are still debated with regard to their persistence in the long term. Moreover, the impact of gender on the response to GH is controversial. Aim of this study was to evaluate the long-term effects of rhGH replacement on bone mass and body composition in a monocentric cohort of patients with AGHD. Methods: Data from 138 patients with AGHD (34.3 ± 14.3 years, 48 women and 90 men) treated with rhGH for a period of at least 3 years up to a maximum of 10 were retrospectively collected. Bone mineral density (BMD) at the lumbar spine, femur, and radius, and total and truncular body composition were evaluated by dual energy X-ray absorption (DXA) before and during treatment. Clinical and laboratory evaluations were performed before and during the treatment period on an annual basis. Results: Lumbar spine BMD consistently increased in males, while in females decreased after a transient improvement observed during the first 4 years of therapy. There were no significant changes in femoral BMD in either sexes, while a progressive increase at radius was observed only in males. Lean mass significantly increased in both sexes, while fat mass decreased only in males. Conclusions: In AGHD patients long-term rhGH replacement therapy induces a positive effect with regard to bone mass and body composition. A sexual dimorphism in the response to treatment is evident, with males displaying more favorable outcome.
No takes yet. Share an insight, caveat, or question.
Rossini et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: